Approximately one-third of Fabry disease patients have cognitive impairments, a feature more common in those who have a deficient blood supply to the brain (called cerebrovascular disease), according to researchers in Denmark. Their study, “Cognitive Impairments and Subjective Cognitive Complaints in Fabry Disease: A Nationwide Study…
News
Transplanting the liver may not be an effective strategy to restore α-galactosidase A (GLA) levels — the deficient enzyme in Fabry disease patients — according to a case report. The report, “Persistent Alpha-galactosidase A Deficiency following Simultaneous Liver-Kidney Transplantation in a Patient with Fabry Disease,” was published…
Galafold (migalastat) significantly reduces diarrhea in patients with Fabry disease and “amenable” mutations — that can respond to Galafold treatment — according to a recent analysis of the FACETS study’s results. This result supports previous evidence from the same trial showing that Galafold improves gastrointestinal symptoms, including diarrhea,…
An enzyme structurally similar to alpha-galactosidase A (GLA), present in a close relative of the tobacco plant, was able to rescue Fabry disease patients’ cells. These findings suggest that plant alpha-galactosidases can be a potential new source for enzyme replacement therapy in Fabry disease. The study “Nicotiana benthamiana α-galactosidase A1.1 can…
Genetic and enzymatic screening of people in Spain revealed that the real prevalence of Fabry disease is likely underestimated, and that late diagnosis is detrimental to patients because of delayed treatment. The study, “Fabry disease in the Spanish population: observational study with detection…
A specific mutation in the GLA gene is associated with late-onset Fabry disease, and primarily affects the heart with more severe symptoms in males, according to researchers who received information from an international Fabry disease registry. Cardiac problems in people carrying this mutation may become…
April is Fabry Disease Awareness Month, and Amicus Therapeutics helped to raise awareness about the disease, as well as Pompe disease, by participating in a series of activities throughout the month. Fabry disease is an inherited lysosomal storage disorder caused by deficiency of an enzyme called alpha-galactosidase A (alpha…
A specific genetic mutation of the GLA gene results in the development of atypical late-onset Fabry disease, a study found. The study, “Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation,” was published in Plos One. Fabry disease is caused by genetic…
Amicus Therapeutics has launched Healing Beyond Disease, an initiative designed to celebrate people living with rare diseases, like Fabry disease, and their loved ones. “We are thrilled and honored to officially launch Healing Beyond Disease, our unique promise to further serve the needs of the rare disease community in extraordinary…
Gastrointestinal specialists should add Fabry disease to their list of possible causes of non-specific gastrointestinal symptoms, according to a review published in the journal Digestive and Liver Disease. The authors suggest that improved diagnostic tools for these symptoms may help the diagnosis of Fabry disease. The recent study, “…
Recent Posts
- Canada approves ERT Elfabrio for adults with Fabry disease
- I work hard to influence my health outcome with Fabry disease
- Canadian study highlights stroke danger for young adults with Fabry
- Fabry treatment ST-920 boosts kidney, heart function in trial
- Echocardiograms may spot early heart disease in Fabry, study finds
- In rare case, woman diagnosed with both Fabry and blood disorder
- Companies challenge EMA advice rejecting monthly Elfabrio dosing
- ERT may protect heart function after Fabry kidney failure
- Helping my children with Fabry find ways to combat depression
- EU agency urges against monthly dosing plan for Fabry drug Elfabrio